459
Views
11
CrossRef citations to date
0
Altmetric
Rat PCO and Ursodeoxycholic Acid

Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model

, , , , , , & show all
Pages 492-497 | Received 22 Jun 2015, Accepted 16 Dec 2015, Published online: 15 Jan 2016

References

  • Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 2010;131:743–60
  • Cerda C, Perez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007;47:412–17
  • Tock L, Carneiro G, Togeiro SM, et al. Obstructive sleep apnea predisposes to nonalcoholic Fatty liver disease in patients with polycystic ovary syndrome. Endocrine Practice 2014;20:244–51
  • Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 2014;20:14172–84
  • Chitturi S. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2008;1:173–89
  • Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clinics Res Hepatol Gastroenterol 2012;36:S3–12
  • Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54:1011–19
  • Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 2010;59:1899–905
  • Mahmoud AA, Elshazly SM. Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. PLoS One 2014;9:e106993
  • Marcondes FK, Bianchi FJ, Tanno AP. Determination of the estrous cycle phases of rats: some helpful considerations. Brazil J Biol 2002;62:609–14
  • Kafali H, Iriadam M, Ozardali I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res 2004;35:103–8
  • Elia E, Sander V, Luchetti CG, et al. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Mol Hum Reprod 2006;12:475–81
  • Atis A, Aydin Y, Ciftci F, et al. Hyberbaric oxygen increases atresia in normal & steroid induced PCO rat ovaries. Reprod Biol Endocrinol 2012;10:11
  • Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
  • Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006;91:2100–4
  • Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013;120:267–76
  • Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007;13:527–37
  • Di Pietro M, Parborell F, Irusta G, et al. Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. Endocrinology 2015;156:1453–63
  • Manneras L, Cajander S, Holmang A, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007;148:3781–91
  • Sasikala SLSS. Unique rat model exhibiting biochemical fluctuations of letrozole induced polycystic ovary syndrome and subsequent treatment with allopathic and ayurvedic medicines. J Cell Tissue Res 2009;9:2013–17
  • Ihedioha JI, Noel-Uneke OA, Ihedioha TE. Reference values for the serum lipid profile of albino rats (Rattus norvegicus) of varied ages and sexes. Compar Clin Pathol 2013;22:939
  • Saha JK, Xia J, Grondin JM, et al. Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models. Exp Biol Med 2005;230:777–84
  • Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79–104
  • Amaral JD, Viana RJ, Ramalho RM, et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009;50:1721–34
  • Amini L, Tehranian N, Movahedin M, et al. Antioxidants and management of polycystic ovary syndrome in Iran: a systematic review of clinical trials. Iran J Reprod Med 2015;13:1–8
  • Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685–97
  • Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219–31
  • Goldman MH, Scheraldi CA, Soule WC. Ovarian hyperthecosis associated with fatty liver disease. Am J Obstet Gynecol 1987;156:1239–40

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.